AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
Two big medicine companies might merge into one super-big company. When companies join together, watch if they have strong medicines coming out soon and if the government will allow the deal—those things affect whether it's actually a good idea.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.